Brought to you by 
Napo licenses AsiaPharm rights to diarrhea treatment
23 Jul 2019
Executive Summary
AsiaPharm Group Ltd. (molecular diversity) licensed exclusive rights from Napo Pharmaceuticals (natural products) to develop, market, and commercialize in China, Hong Kong, and Macau crofelemer-based therapeutics for AIDS-related diarrhea, acute infectious diarrhea, and pediatric diarrhea.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Napo licenses AsiaPharm rights to diarrhea treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice